ERYP - Erytech's late-stage pancreatic cancer study will continue to final analysis

Erytech Pharma's (ERYP) Phase 3 clinical trial TRYbeCA-1, evaluating eryaspase in second-line pancreatic cancer will continue without modification following a planned interim superiority analysis conducted by an Independent Data Monitoring Committee ((IDMC)). The interim analysis was triggered following the occurrence of two-thirds of the events and allowed the potential for stopping the trial early if the primary endpoint reached statistical significance, adjusting the statistical threshold for the interim review.The primary endpoint is overall survival. TRYbeCA-1 trial is fully enrolled and the Company continues to expect the final analysis in Q4 2021.No safety issues have been identified which is consistent with observations in previous IDMC reviews. “The trial will now continue to the final efficacy analysis. With 512 patients enrolled, the trial has approximately 90% power to detect the trial’s design hazard ratio of 0.725," said Gil Beyen, CEO.

For further details see:

Erytech's late-stage pancreatic cancer study will continue to final analysis